Evaluation and Management of Palpable Breast Masses

Introduction to Breast Mass Evaluation

The American College of Radiology recommends that a breast mass palpable during menstruation be evaluated with imaging to exclude malignancy, as physical examination alone is unreliable, with only 58% of palpable cysts correctly identified by physical examination 1, 2

A simple cyst cannot be reliably distinguished from solid masses by palpation alone, and only 58% of palpable cysts are correctly identified by physical examination 1, 2
Fibroadenoma is typically mobile with discrete, well-defined margins and soft or rubbery texture 2
Fat necrosis or oil cyst may present as a palpable finding 1
Invasive breast cancer can present as a palpable mass even in younger women, though less common 2

For women under 30 years, the American College of Radiology recommends starting with targeted breast ultrasound as the initial imaging study to avoid unnecessary radiation exposure 3, 4
For women 30-39 years, either ultrasound or diagnostic mammography may be performed first, depending on clinical suspicion 2, 3
For women ≥40 years, diagnostic mammography followed by targeted ultrasound is the standard approach, with mammography sensitivity alone being 86-91% for palpable abnormalities 1, 2, 5

If a simple cyst is identified on ultrasound, return to routine clinical follow-up only, with no further imaging, short-interval follow-up, or biopsy needed 6, 3, 4
If a solid mass with benign features is identified, perform short-interval ultrasound follow-up at 6 months, then every 6-12 months for 1-2 years 6, 3, 4
If suspicious features are identified, proceed directly to ultrasound-guided core needle biopsy, which is classified as BI-RADS 4-5 6, 3, 4

Concordance verification is mandatory, ensuring agreement between pathology results, imaging findings, and clinical examination 6, 3
If discordance exists, pursue additional tissue sampling or surgical excision 6, 3

Never delay imaging evaluation, as physical examination alone is unreliable, and imaging is necessary in almost all cases to characterize palpable lesions 4
Never assume benignity based solely on clinical features, such as cyclic changes or soft texture 4
Never perform biopsy before imaging, as biopsy-related changes will confuse subsequent image interpretation 1, 7, 4
Never rely on a single imaging modality, as mammography and ultrasound provide complementary information 6
Do not order MRI, PET, or molecular breast imaging as initial evaluation, as these have no role in the routine workup of a palpable mass 5, 7, 4